Plain-English translation of NCT06164314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , a medication that helps calm the nervous system, can prevent delirium (severe confusion and disorientation) after brain tumor surgery. About 366 patients will receive either the medication or a placebo during and for 48 hours after their surgery. The researchers want to see if this treatment helps patients stay mentally clear and recover better.
Delirium after brain surgery is common and can be frightening for patients and families. It can slow recovery and sometimes cause lasting problems. This study aims to see if this medication might help prevent that confusion from happening in the first place.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive either the medication or a placebo starting right after you go to sleep for surgery and continuing through the closing of your surgical wound. For the next 48 hours after surgery, you'll receive either the medication or placebo through an IV along with pain relief medication. Researchers will track your mental clarity and recovery during your hospital stay to see if the treatment helped prevent confusion.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Beijing Tiantan Hospital
Enrollment target
~366 participants
Started
January 2024
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuming Peng
Beijing Tiantan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.